Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Eli Lilly and Company
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center
Fondazione del Piemonte per l'Oncologia
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Pfizer
Pfizer
Mayo Clinic
Centre Oscar Lambret
PMV Pharmaceuticals, Inc
Mayo Clinic
Hoffmann-La Roche
University of California, Irvine
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Pfizer
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
Clasp Therapeutics, Inc.
OHSU Knight Cancer Institute
Baylor College of Medicine
University of Colorado, Denver
SystImmune Inc.
UNC Lineberger Comprehensive Cancer Center
Daiichi Sankyo
Grey Wolf Therapeutics
Kidney Cancer Research Bureau
Second Life Therapeutics
M.D. Anderson Cancer Center
AgonOx, Inc.
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Novartis
Sichuan Baili Pharmaceutical Co., Ltd.
Var2 Pharmaceuticals
Inhibrx Biosciences, Inc
Seagen Inc.
VM Oncology, LLC
RenJi Hospital
Degron Therapeutics Co.
Takeda
Cancer Research UK
Petrov, Andrey
Shasqi, Inc.